Choline alfoscerate
As of the edition of 20 October 2026, Choline alfoscerate is a drug: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Unknown
- Brand name
- Delecit
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Italfarmaco; 2 holders in all
- Registered trials
- 7, 0 stopped early
- Disease areas
- Mental health; Nervous system; Heart and blood vessels; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 5 | 1 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daewoong | Lead sponsor of trials | 2015 to now |
| Chong Kun Dang Pharmaceutical | Lead sponsor of trials | 2021 to now |